Lushang Freda Pharmaceutical Co (SHSE:600223) Total Operating Expense: ¥1,797 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600223 Lushang Freda Pharmaceutical Co Ltd SHSE:600223
68 GF Score
Price ¥5.49
GF Value ¥6.56
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lushang Freda Pharmaceutical Co Total Operating Expense?

Lushang Freda Pharmaceutical Co SHSE:600223 68 Total Operating Expense is ¥1,797 Mil as of Mar. 2026. GuruFocus rates SHSE:600223 with a GF Score™ of 68/100 and a GF Value™ of ¥6.56 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Lushang Freda Pharmaceutical Co's Total Operating Expense for the three months ended in Mar. 2026 was ¥473 Mil. Lushang Freda Pharmaceutical Co's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1,797 Mil.

Lushang Freda Pharmaceutical Co Total Operating Expense Related Terms

Lushang Freda Pharmaceutical Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Lushang Freda Pharmaceutical Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lushang Freda Pharmaceutical Co Total Operating Expense Chart

Lushang Freda Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,312.17 2,310.67 1,820.04 1,820.67 1,717.99

Lushang Freda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 394.31 422.71 378.37 522.60 473.04
SHSE:600223
68GF Score
Lushang Freda Pharmaceutical Co Ltd SHSE:600223
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lushang Freda Pharmaceutical Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,797 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ¥1,797 Mil mean?
Lushang Freda Pharmaceutical Co (SHSE:600223) has a Total Operating Expense of ¥1,797 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Lushang Freda Pharmaceutical Co and its competitors.
Is Lushang Freda Pharmaceutical Co's Total Operating Expense too high?
Lushang Freda Pharmaceutical Co's current Total Operating Expense is ¥1,797 Mil. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's Total Operating Expense compare to competitors?
Lushang Freda Pharmaceutical Co's Total Operating Expense of ¥1,797 Mil can be compared against companies in the Real Estate industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Real Estate company?
A good Total Operating Expense depends on the Real Estate industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Lushang Freda Pharmaceutical Co and its competitors. Lushang Freda Pharmaceutical Co's current Total Operating Expense is ¥1,797 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.56, compared to a current price of ¥5.49 — trading 16.3% below its estimated fair value. The current Total Operating Expense is ¥1,797 Mil. Lushang Freda Pharmaceutical Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current Total Operating Expense is ¥1,797 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?

Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥5.49 is trading 16.3% below its estimated GF Value™ of ¥6.56. GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600223:

  • Total Operating Expense: ¥1,797 Mil
  • GF Value™: ¥6.56 vs. price of ¥5.49 (16.3% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lushang Freda Pharmaceutical Co Business Description

Address No. 9777 Jingshi Road, Building 5, Lixia District, Jinan City, CHN
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
68GF Score

Get the complete analysis for SHSE:600223

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.49
Price
¥6.56
GF Value